Description
BPIQ-I is a quinazoline that inhibits the tyrosine kinase activity of the epidermal growth factor receptor (IC
50 = 0.025 nM). It can inhibit the growth of SKOV3 and MDA-468 tumor cell lines with EC
50 values of 6.5 and 30 μM, respectively.
Uses
BPIQ-I (PD 159121) is a potent and ATP-competitive EGFR tyrosine kinase inhibitor.. BPIQ-I shows anti-proliferative actively[1][2].
References
[1] Rae JM, et al. Evaluation of novel epidermal growth factor receptor tyrosine kinase inhibitors. Breast Cancer Res Treat. 2004 Jan;83(2):99-107. DOI:
10.1023/B:BREA.0000010702.10130.29[2] Zhou Y, et al. Role of a tyrosine kinase in the CO2-induced stimulation of HCO3- reabsorption by rabbit S2 proximal tubules. Am J Physiol Renal Physiol. 2006 Aug;291(2):F358-67. DOI:
10.1152/ajprenal.00520.2005
